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SUMMARY
The objective of this study was to evaluate the weight gain
effect of Periactin tablets in anorexic patients. Periactin
doses of 2 mg, 4 mg and 8 mg were found to be statistically
significantly better than placebo in regard to weight gain.
Periactin 4-mg and 8-mg dosage groups showed a statisti-
cally significantly higher incidence of total side-effects and
drowsiness than placebo, Periactin 2 mg and 4 mg (2 mg
in morning, 2 mg in evening). A dosage of 2 mg b.d. was
found to be adequate to ensure substantial weight increase
while side-effects were virtually absent.
The appetite- and growth-stimulating properties of Periactin
(cyproheptadine) were first reported by Lavenstein et al.'
in 1962. During clinical evaluation of cyproheptadine, an
antagonist of histamine and serotonin, these investigators
noted significant weight gain and height increase and an
accelerated linear growth rate in 28 outpatient asthmatic
children. In studying the appetite-stimulating properties of
cyproheptadine, Bergen' also confirmed increase in appetite
and weight gain. The mechanism of this phenomenon is
unclear; however, it seemed possible that this agent might
have a hypoglycaemic action that in turn induces hyper-
phagia. The weight gain was apparently a reflection of
simple exogenous obesity and no evidence of fluid retention
could be detected.
In consequence, Periactin has recently been marketed as
an appetite stimulant. The research committee of the Cape
of Good Hope Faculty of the South African College of
General Practitioners undertook a survey to determine the
optimum dosage required to ensure adequate appetite
stimulation and weight gain without undesirable side-
effects.
MATERIALS AND METHODS
The survey comprised a double-blind, non-cross-over study
with a placebo. The drugs used were Periactin 2 mg and
4 mg, and a placebo as a control agent. The study in-
cluded 81 underweight patients of both sexes and of all
age-groups whose underweight was due to loss of appetite
or anorexia. Loss of appetite may have been due to
physiological reasons, psychoneurotic or psychopathologi-
cal illness; included also were convalescents after illness.
The study was conducted over 3 months, during which
time patients received continuous therapy. The degree of
appetite stimulation and weight gain was observed during
this period and any observed or volunteered side-effects
were recorded at each visit. Drowsiness was especially
noted when it occurred. Patients were seen at weekly
intervals after they were given a randomly allocated study
treatment denoted by a serial number. Patients were thus
examined at weeks ° (pre-treatment), I, 2, 3, 4, 6, 8, 10,
12 and 16. However, only at weeks 2, 4, 8, and 12 were
enough patients examined for a statistical analysis to be
*Date received: 4 November 1970.
performed. At each examination date, weight measure-
ments and appetite appraisal were made. The study treat-
ment comprised specially marked and coded bottles con-
taining e:ther 2-mg tablets or 4-mg tablets of Periactin or
alternatively identical-looking placebo tablets. Patients took
their medication before meals at a dose of 2 tablets per day
and in this manner the total daily dosage was 2 mg, 4 mg,
8 mg or placebo.
Appetite scoring was: a-none; I-fair; 2-good; 3-
very good; and 4-ferocious. Adverse reactions noted were
drowsiness, dizziness and dry mouth. These side-effects
were mild and usually transient. In only 1 case was medi-
cation discontinued because of side-effects and this patient
turned out to be psychotic.
RESULTS
The results were divided into 5 categories:
Group I: Patients receiving 2 mg Periactin tablets morn-
ing and placebo evening.
Group Il: Patients receiving 2 mg Periactin tablets
morning and evening.
Group Ill: Patients receiving placebo.
Group IV: Patients receiving 4 mg Periact;n tablets
morning and evening.
Group V: Patients receiving 4 mg Periactin tablets
morning and placebo evening.
Table I gives a breakdown by age and sex for each treat-
ment group. The groups were not comparable as to age
distribution. The median age of group IV was found to
be statistically significantly greater than that of groups I
and Il and the median age of group V was found to be
TABLE I. AGE AND SEX OF PATIENTS IN EACH TREATMENT GROUP
Sex
No. of Age Median
patients M F range aRe*
Group I 17 9 8 3 - 25 9
Group II 16 5 1I 4·5 - ,1 12·5
Group III 16 10 6 5 - 24 14
Group IV 16 3 13 12 - 29 18
Group V 16 6 10 4·5 - 43 18
"'Determined by rank sum test. 3
statistically significantly greater than that of group I.
For statistical reasons, a logarithmic transformation was
made on the weight-gain data. Table Il shows the geometric
mean weights and percentage increases in geometric mean
weights adjusted by analysis of covariance where appro-
priate (i.e.· significant over-all reduction in variance and
parallel regressions). All Periactin doses showed statisti-
cally significantly greater percentage increases in weight
than the placebo group at weeks 8 and 12. The percentage
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46·28 47·89 68'10 70·01
58·12 60'70 68'10 70·93
78'13 78'25 68·\0 68·37
95·75 98·07 68'10 70·15






54·29 58'16 74·09 77·82
58·92 64·81 74·09 80·31
69-67 70·03 74·09 74·19
96·70 103-63 74·09 80·76
97·10 101'23 74·09 78·58
56·88 62'52 75·56 81·17
59·64 66-47 75·56 82·61
69·59 70'90 75·56 76·47
96·84 105·55 75·56 84·02























*Adjusted by analysis of covariance for differences in pre-treatment values.
tStatistically significantly better than placebO (group lm, P<0·05.
;Statistically significantly better than placebo (group ill), P<;:O·Ol.
TABLE Ill. GROUP 1. PATIENTS RECEIVING PERlACfIN 2 mg MORNING AND PACEBO IN THE EVENlNG*
GailC 1st Gain 2nd Weight change
month month ill 3 months
Serial No. Age Sex (lb) (lb) (lb) Appetite
1 7t F + Ot + Ot 0
6 13 F + 2 + Ot + 5t +
II 21 F + 6 3 + 5 0
16 3 M + It + Ot + 2 0
22 25 F + 3 + It + 8 ++
26 14 F 2 0 2 0
39 4 M + 3 + Ot + 6 +
32 3 M
41 13 1-1 + 4 + I + 5t ++
46 6 F + 1 + 2 + 4 ++
52 3 M + 2t + I-} + 4{· +
57 4 F + ot + 2 + 2+ +
65 7 J\1 + It + It + 3 0
73 4 M + 2 + 3 + 5t +
78 16 M + 1 I + 1 0
80 9 F + It + ot + 1--4- 0


















*17 patients were !ncluded in this category. 9 males and 8 !en1ales; l~ patients co~np~eted the 3-J~10nt~ ... treatment .period.. I
Average weight gain: 1st month +1·81 Ib; 2nd month +0'7,; total weight change In ,·rnomh penod -"'3 ; appellte sconng T 1; side-effects 1.
larger, which could be related, however, to the lack of
comparability of the groups as to age. The results are set
out in Tables II - VU.
CONCLUSIONS
The results of this survey indicate that all treatment
schedules were superior to placebos. Patients in group IV
receiving 4 mg Periactin h.d. showed the greatest effect as
regards appetite stimulation and weight gain. However. the
incidence of transient drowsiness was highest in this group.
Patients in group n receiving 2 mg Periactin h.d. showed
a very marked response with hardly any side-effects. Tn
this latter group no side-effects were recorded in the
paediatric age-groups, viz. 12 years and under.
Periactin in the dosage of 2 mg h.d. thus ensures marked
weight increase with minimal side-effects.
The research committee of the Cape of Good Hope Faculty
of General Practitioners wishes to thank Messrs Merck
Sharpe & Dohme for providing the drugs used in this trial
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TABLE IV. GROUP 11: PATIEl\'TS RECEIVING PERIACTIN 2 mg TABLETS MORNING AND EVE ING*
Gain Gain 2nd Weight change
1st mO/llh mOlllh in 3 months
Serial No. Age Sex (lb) (lb) (lb) Appetite Side-effects
3 18 F + 3 0 + 3 + ++
8 24 F + 4 2 + 4 + 0
13 19 F + 4 + 2 + 6 ++ 0
19 25 F + 7 + I + 9 ++ 0
24 8 F + 3 + 3 + 7 ++ 0
29 14 M + 12 + 3 + 15 ' , 0T,
36 4t 1\1 + I 0 + 2 ++ 0
43 7 F + 3t + I + 5 ++ 0
48 5 F + 3 + 2 + 5t ++ 0
51 6 F + 4t + I + 7t ' , 0T,
56 5 F + 2 + 2 + 4 + 0
63 31 F + 8 + 10 + 12 ++ 0
70 10 F + 5 + I + 7 ++ 0
75 9 F + 3t , 3t + 0
85 6 F + I
90 9 M + 5 + 2 + 8 ++ a
'* 16 patients were included in this group; one failed IQ complete the 3 months' therapy.
+6·56; appetite scoring +2; side-effects-IAverage weight gain: 1st nl0nth +4·34 Ib; 2nd month +1·86; total weight change in 3-month period
patient complained of drowsiness.
TABLE V. GROUP Ill: PATIENTS RECEIVING PLACEBO MORNING AND EVENING*
Gain Gain 2nd Weight change
1st mO/llh month in 3 months
Serial No. Age Sex (lb) (lb) (lb) Appetite Side-effects
2 22 M 3 + 2 0 0 a
7 19 F + 2 0 + 2 + 0
15 12 M 0 0 + I 0 0
18 19 M 2 4 10 0 0
21 5 M O-} + Ot + Ot 0 a
30 24 F + ot 0 + 3 0 0
34 6 M + 1 0 + 2 0 0
37 9 M + 3 at + 2t + 0
53 14 M + I
60 6 F 0 0 0 0 0
62 13 T' + I 0 0 0 0
74 9 ·1 + 1 0 + 1 0 0
81 16 M 1
83 8 F + H 0 + It + 0
87 23 F + It + ut + 2 + 0
'* 15 patients were inc:uded in this category; 9 males and 6 fema!es.
Average weight gain: 1st month +0-40 lb; 2nd month -0-12; total weight change in 3-month period +0·42; appetite scoring 0; side-effects o.
TABLE VI. GROUP IV: PATIENTS RECEIVING PERIACTIN 4 mg TABLETS MORNING AND EVENING"
Gain Gain 2nd Weight change
1st mO/ll1t month in 3 months
Serial No. Age Sex (lb) (lb) (lb) Appetite Side-effects
5 24 M + 5 + 2 + 8 +++ 1
12 12 M + I 0 + I 0 0
17 22 F + 5 + 2 + 10 ++ 0
?' 18 F + 4 + 6 + 28 +++ 0_J
28 17 F + 6 0 + 11 +7+ 0
35 17 F 2 1 4 + 0
40 14 F + 10 + 3 + 15 +++ 1
45 18 F + 4 + 3 + 7 ++ 0
50 18 F + 3 + It + 4 ++ 0
55 14 M + 3 + 4 + 8 +++ 1
58 29 F + 10 0 + 13 ++ 1
64 18 F .,
69 25 F + 3 + 3 + 1
71 17 F + 6 + 3 + 10 +++ 1
76 19 F + 14 + 2 + 19 +++ a
82 21 F + 5 0 + 8 + 1
*16 patients were included in this category. 3 males and 13 females.
Average weight gain: Is! month +5·13 Ib; 2nd month +1· 2; rotal weight change in 3-month period +9·40; appetite scoring +2; side-effects-5
patients complained of transient drowsiness.
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TABLE VII. GROUP V' PATIENTS RECEIVING PERIACTIN 4 mg MORNING AND PLACEBO IN THE EVE."IING*
Gain Gain 2nd Weight change
ht monrh monrh in 3 mOlllhs
Serial No. Age Sex (lb) (lb) (lb) Appetite Side-effects
4 21 F + 7 8 + 8 0 014 21 F + ~.1. + It + 5 ++ 0-'220 18 F + 4 + 2 + 6 ++ I25 7 M + It 0 + 3t + I27 24 F + 1 I + I 0 031 28 M + I + I + H ++ 038 17 M + 4 I + 4- + ++
44 44 F 0 0 2 + 049 4t F +54 31 F + 3 + 2 + 4 ++ 059 11 F + 3 + 1 + 4 0 ++61 12t M + 2 + 4 + 8 ++ ++
72 ?~ M + 2 + I + 4 + +--'77 4 M + 3 + Ot + ~..l. + +-'284 20 F + 11 + I + 11 ++ +88 12 F + 4 + 2 + 7 ++ 1
.. 16 patients were included in this category. 6 males and 10 females.
Average 'Yeight gain: ~st month .+3'33 Ib; 2nd month +0'40; total weight change in 3-month period +4-57; appetite scoring +2: side-effects-lO patients
complalDed of transient drowsmess.
and for their assistance in the statistical evaluation. The com-
mittee also wishes to thank Dr P. Goosen, Medical Director
of Merck, Sharpe & Dohme. for his assistance: and Drs F,
Domfest, P. Honeywill and A. W. Spratt for submitting data.
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DIET, BOWEL MOTILITY, FAECES COMPOSITION AND COLONIC CANCER*
A. R. P. WALKER, MRC Human Biochemistry Research Unit, South African Institute for Medical Research,
Johannesburg
SUMMARY
The commonness of colonic cancer in privileged popula-
tions compared with its rarity in those pursuing a primitive
manner of life suggests that environmental factors are
primarily responsible. In this study, differences in diet
and their ramificarions are discussed in relation to popu-
lations prone and less prone to the disease. Some possible
hypotheses of causation are considered. It is concluded
that in the present contexts of western populations, in so
far as diet directly or indirectly is involved, there is little
or no likelihood of lowering the present high preva!ence
of cancer of the colon.
Recent contributions by Higginson,' Wynder and co-
workers",3 Burkitt: and also editorial comment"· have
underlined the present high mortality from cancer of the
colon in western populations. The disease is now respon-
sible for 2 - 3% of all deaths; it accounts for about 15°~
of all deaths from cancer, being second only to lung
cancer.'" Several questions arise. Firstly, what aetiological
leads are suggested by the epidemiology of the disease?
Secondly, how do populations with contrasting prevalences
of the disease differ, not only in diet and manner of life,
but more particularly, in bowel motility, faeces composi-
tion and related parameters? Thirdly, in the light of such
knowledge, what are the possible causes of the disease?
Fourthly. and most important, in so far as diet is impli-
cated, is there any likelihood of preventing or of retarding
the development of colonic cancer?
'pate re~ived: 20 July 1970.
PREVALENCE
During the last century, mortality has increased con-
siderably; examination of the data available suggests that
the increase is due only in part to the ageing of popula-
tions. Among technically retarded populations prevalence
is low, constituting as little as I % of all cancers.',·,T,S
Prevalence rises when less privileged populations migrate
to prosperous regions.' Within countries, both western and
underdeveloped, the condition is more prevalent in large
towns compared with country districts."· As Burkitt' has
emphasized, the foregoing evidence indicates that the
causative or promotive factors are largely, if not wholly.
environmental. In the contrasting populations cited, the
salient differences in environmental factors concern diet.
physical activity, smoking and stress.
DIETARY DIFFERENCE
The diet consumed by primitives or the less privileged
differs markedly from that eaten by sophisticated popu-
lations. Tu the problem at issue perhaps the most plausible
difference is the far greater frequency of exposure of the
latter to chemicals involved in food production and pre-
servation, also to industrial and other pollution. Pre-
occupation with this possible source of carcinogens,
however, has tended to obscure other dietary changes
which may well be influential, yet whose physiological
ramifications are insufficiently appreciated. Broadly, the
diet of underprivileged populations is lower in calories, in
animal protein and often total protein, and in animal as
well as total fat. It has higher concentrations of less re-
fined carbohydrate foodstuffs, and also of crude fibre. It
